Last reviewed · How we verify
NCT07444099
Early Postoperative Intervention in Gastric Cancer Patients
NA trial testing Early structured postoperative intervention encompassing nutrition, psychology, and exercise in Gastric Cancer (GC) in 264 participants. Enrolling by invitation.
10 March 2027
Quick facts
| Lead sponsor | Qilu Hospital of Shandong University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 264 |
| Start date | 10 February 2026 |
| Primary completion | 10 March 2027 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Early structured postoperative intervention encompassing nutrition, psychology, and exercise
Conditions studied
- Gastric Cancer (GC) — all drugs for Gastric Cancer (GC) →
- Postoperative Recovery — all drugs for Postoperative Recovery →
Sponsor
Qilu Hospital of Shandong University
Who can join
Adults 18 to 80, any sex, with Gastric Cancer (GC) or Postoperative Recovery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was conducted by Qilu Hospital and five other renowned medical centers, aiming to evaluate the impact of early structured postoperative intervention on quality of life and prognosis in patients with gastric cancer after neoadjuvant therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07444099
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer (GC)
Currently open trials in the same condition.
- NCT07522320 — Costs of Opportunistic Upper Gastrointestinal Endoscopy and the Economic Burden of Gastric Cancer Management · active not recruiting
- NCT07311408 — SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure · Phase 2 · recruiting
- NCT07366528 — Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer · Phase 3 · recruiting
- NCT07313579 — Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer · recruiting
- NCT07217704 — Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. · Phase 3 · recruiting
Other Qilu Hospital of Shandong University trials
Trials by the same sponsor.
- NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
- NCT07140419 — Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. · NA · not yet recruiting
- NCT07509879 — Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder · not yet recruiting
- NCT07537374 — A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Develo · not yet recruiting
- NCT07505940 — Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07444099 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qilu Hospital of Shandong University
- Last refreshed: 2 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07444099.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing